What is Sinovent, Inc.?
Founded in 2017 and headquartered in Suzhou, China, Sinovent, Inc. operates as a biopharmaceutical and clinical research company. Its focus lies in advancing drug discovery and development, leveraging clinical research to bring innovative therapies to market. The company's strategic positioning within the rapidly evolving healthcare landscape suggests a commitment to addressing unmet medical needs through scientific rigor and advanced research methodologies. This enterprise-level backing positions Sinovent to scale its operations and accelerate its pipeline.
How much funding has Sinovent, Inc. raised?
Sinovent, Inc. has raised a total of $243.1M across 2 funding rounds:
Series C
$145M
Series E
$98.1M
Series C (2020): $145M with participation from Oceanpine Capital, CICC Qide Innovation Biopharmaceutical Equity Invesment Fund, Jiuyo Capital, and Loyal Valley Capital
Series E (2024): $98.1M, investors not publicly disclosed
Key Investors in Sinovent, Inc.
Oceanpine Capital
Oceanpine Capital is a professional investment management firm focused on long-term value creation, specializing in high-growth enterprises and startups across TMT, consumption upgrade, advanced manufacturing, and healthcare sectors.
CICC Qide Innovation Biopharmaceutical Equity Invesment Fund
CICC Qide Innovation Biopharmaceutical Equity Invesment Fund is an investment vehicle focused on the biopharmaceutical sector, likely supporting companies with innovative drug development pipelines.
Jiuyo Capital
Jiuyo Capital is an investment firm that has participated in Sinovent, Inc.'s funding rounds, contributing to the company's growth capital.
What's next for Sinovent, Inc.?
With the recent influx of capital, Sinovent, Inc. is poised for significant expansion and advancement in its research and development programs. The major strategic investment signals a strong endorsement of the company's long-term vision and its potential to disrupt the biopharmaceutical market. Future endeavors will likely involve accelerating clinical trials, expanding research capabilities, and potentially forging new strategic partnerships to enhance its drug development pipeline. This sustained financial backing is critical for navigating the complex and capital-intensive biopharmaceutical industry, enabling Sinovent to pursue ambitious growth strategies and solidify its market presence.
See full Sinovent, Inc. company page
